High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases

Abstract Background: High platelet reactivity (HPR) during therapy with acetylsalicylic acid (ASA) is a poor prognostic factor in acute coronary syndromes (ACS). The prevalence of HPR during ACS is greater than that reported in stable diseases. However, it is unclear whether this prevalence of HPR...

Full description

Bibliographic Details
Main Authors: Marianna Deway Andrade Dracoulakis, Paul Gurbel, Marco Cattaneo, Herlon Saraiva Martins, José Carlos Nicolau, Roberto Kalil Filho
Format: Article
Language:English
Published: Sociedade Brasileira de Cardiologia (SBC)
Series:Arquivos Brasileiros de Cardiologia
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2019005014103&lng=en&tlng=en
_version_ 1828282862793654272
author Marianna Deway Andrade Dracoulakis
Paul Gurbel
Marco Cattaneo
Herlon Saraiva Martins
José Carlos Nicolau
Roberto Kalil Filho
author_facet Marianna Deway Andrade Dracoulakis
Paul Gurbel
Marco Cattaneo
Herlon Saraiva Martins
José Carlos Nicolau
Roberto Kalil Filho
author_sort Marianna Deway Andrade Dracoulakis
collection DOAJ
description Abstract Background: High platelet reactivity (HPR) during therapy with acetylsalicylic acid (ASA) is a poor prognostic factor in acute coronary syndromes (ACS). The prevalence of HPR during ACS is greater than that reported in stable diseases. However, it is unclear whether this prevalence of HPR is a transient phenomenon or a characteristic of this high-risk population. Objective: The main objective is to compare the effects of ASA on platelet function in the initial and late phases of ACS in a single population. Secondary objectives are: correlation between the tests between themselves and the relationship between the tests and the variation of the inflammatory markers (C-reactive protein and interleukin-6). Methods: Seventy patients with non-ST segment elevation (NSTE) ACS in use of 100-200 mg of ASA per day for at least 7 days were prospectively studied. Platelet function was assessed in the first 48 hours and subsequently after 3 months using four methods: VerifyNow™ (VFN), whole blood platelet aggregation (WBPA) with arachidonic acid (AA) and collagen as agonists, and platelet function analyzer (PFA). The level of statistical significance considered was < 0.05. Results: According to the more specific methods (WBPA with AA and VFN), the incidence of HPR was significantly higher in the early phase than in the late phase: WBPA with AA: 31% versus 13%, p = 0.015; VFN: 32% versus 16%, p = 0.049. The other methods tested, which were less specific for ASA, did not show significant differences between phases. The correlation between the methods was weak or moderate (r ranging from 0.3 to 0.5, p < 0.05), and there were no significant associations between HPR and inflammatory markers. Conclusion: The prevalence of HPR during AAS therapy, assessed by specific methods for cyclooxygenase 1 (COX-1), is higher during the acute phase than in the late phase of NSTE ACS.
first_indexed 2024-04-13T08:35:39Z
format Article
id doaj.art-8e8f5441d1bd431cb9cedd01c9f36934
institution Directory Open Access Journal
issn 1678-4170
language English
last_indexed 2024-04-13T08:35:39Z
publisher Sociedade Brasileira de Cardiologia (SBC)
record_format Article
series Arquivos Brasileiros de Cardiologia
spelling doaj.art-8e8f5441d1bd431cb9cedd01c9f369342022-12-22T02:54:06ZengSociedade Brasileira de Cardiologia (SBC)Arquivos Brasileiros de Cardiologia1678-417010.5935/abc.20190146S0066-782X2019005014103High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late PhasesMarianna Deway Andrade DracoulakisPaul GurbelMarco CattaneoHerlon Saraiva MartinsJosé Carlos NicolauRoberto Kalil FilhoAbstract Background: High platelet reactivity (HPR) during therapy with acetylsalicylic acid (ASA) is a poor prognostic factor in acute coronary syndromes (ACS). The prevalence of HPR during ACS is greater than that reported in stable diseases. However, it is unclear whether this prevalence of HPR is a transient phenomenon or a characteristic of this high-risk population. Objective: The main objective is to compare the effects of ASA on platelet function in the initial and late phases of ACS in a single population. Secondary objectives are: correlation between the tests between themselves and the relationship between the tests and the variation of the inflammatory markers (C-reactive protein and interleukin-6). Methods: Seventy patients with non-ST segment elevation (NSTE) ACS in use of 100-200 mg of ASA per day for at least 7 days were prospectively studied. Platelet function was assessed in the first 48 hours and subsequently after 3 months using four methods: VerifyNow™ (VFN), whole blood platelet aggregation (WBPA) with arachidonic acid (AA) and collagen as agonists, and platelet function analyzer (PFA). The level of statistical significance considered was < 0.05. Results: According to the more specific methods (WBPA with AA and VFN), the incidence of HPR was significantly higher in the early phase than in the late phase: WBPA with AA: 31% versus 13%, p = 0.015; VFN: 32% versus 16%, p = 0.049. The other methods tested, which were less specific for ASA, did not show significant differences between phases. The correlation between the methods was weak or moderate (r ranging from 0.3 to 0.5, p < 0.05), and there were no significant associations between HPR and inflammatory markers. Conclusion: The prevalence of HPR during AAS therapy, assessed by specific methods for cyclooxygenase 1 (COX-1), is higher during the acute phase than in the late phase of NSTE ACS.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2019005014103&lng=en&tlng=enSíndrome Coronariana AgudaAgregação PlaquetáriaIsquemia MiocárdicaIdosoAspirina/uso terapêuticoAspirina/efeitos adversos
spellingShingle Marianna Deway Andrade Dracoulakis
Paul Gurbel
Marco Cattaneo
Herlon Saraiva Martins
José Carlos Nicolau
Roberto Kalil Filho
High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases
Arquivos Brasileiros de Cardiologia
Síndrome Coronariana Aguda
Agregação Plaquetária
Isquemia Miocárdica
Idoso
Aspirina/uso terapêutico
Aspirina/efeitos adversos
title High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases
title_full High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases
title_fullStr High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases
title_full_unstemmed High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases
title_short High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases
title_sort high residual platelet reactivity during aspirin therapy in patients with non st segment elevation acute coronary syndrome comparison between initial and late phases
topic Síndrome Coronariana Aguda
Agregação Plaquetária
Isquemia Miocárdica
Idoso
Aspirina/uso terapêutico
Aspirina/efeitos adversos
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2019005014103&lng=en&tlng=en
work_keys_str_mv AT mariannadewayandradedracoulakis highresidualplateletreactivityduringaspirintherapyinpatientswithnonstsegmentelevationacutecoronarysyndromecomparisonbetweeninitialandlatephases
AT paulgurbel highresidualplateletreactivityduringaspirintherapyinpatientswithnonstsegmentelevationacutecoronarysyndromecomparisonbetweeninitialandlatephases
AT marcocattaneo highresidualplateletreactivityduringaspirintherapyinpatientswithnonstsegmentelevationacutecoronarysyndromecomparisonbetweeninitialandlatephases
AT herlonsaraivamartins highresidualplateletreactivityduringaspirintherapyinpatientswithnonstsegmentelevationacutecoronarysyndromecomparisonbetweeninitialandlatephases
AT josecarlosnicolau highresidualplateletreactivityduringaspirintherapyinpatientswithnonstsegmentelevationacutecoronarysyndromecomparisonbetweeninitialandlatephases
AT robertokalilfilho highresidualplateletreactivityduringaspirintherapyinpatientswithnonstsegmentelevationacutecoronarysyndromecomparisonbetweeninitialandlatephases